Status:
COMPLETED
A Study of LY3471851 in Healthy Participants
Lead Sponsor:
Nektar Therapeutics
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
20-64 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to explore the safety and tolerability of LY3471851 in healthy Japanese and Caucasian participants. The study will also estimate how much LY3471851 gets into the bloo...
Eligibility Criteria
Inclusion
- Are healthy males or females, as determined by medical history and physical examination
- Are first generation Japanese or are Caucasian
- Have a body mass index (BMI) of 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive, at the time of screening
Exclusion
- Are currently enrolled in a clinical study involving an investigational product (IP) or any other type of medical research judged not to be scientifically or medically compatible with this study
- Have an abnormal blood pressure and/or pulse rate as determined by the investigator
- Regularly use known drugs of abuse and/or show positive findings on drug screening
- Are immunocompromised per investigator judgment
Key Trial Info
Start Date :
October 29 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 6 2020
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT04133116
Start Date
October 29 2019
End Date
March 6 2020
Last Update
November 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
WCCT Global
Cypress, California, United States, 90630